МЕЙЕРИНК Хендрик Ян Корнелис (NL),ХАНГУР Лекрам (NL)
申请号：
RU2013144749/15
公开号：
RU2013144749A
申请日:
2012.03.06
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A pharmaceutical composition comprising a physiologically acceptable organic and / or inorganic vanadium compound or a complex for use to maintain normoglycemia in a critical patient suffering from acute stress. The pharmaceutical composition of claim 1, wherein the critically ill patient does not suffer from diabetes. The pharmaceutical composition of claim 1, wherein acute stress is caused by damage, stroke, trauma, medical treatment, infection, stroke, coronary artery bypass surgery, or treatment of myocardial infarction. The pharmaceutical composition according to claim 1, wherein the blood glucose levels are maintained between about 80 and about 110 mg / dl (from about 4.4 to about 6.1 mmol / L). The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered parenterally or intravenously. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered for one to seven days. The pharmaceutical composition according to claim 6, wherein critically ill patients are hospitalized in the intensive care unit (ICU). The pharmaceutical composition of claim 1, further comprising insulin or an insulin analogue. The pharmaceutical composition of claim 1, further comprising an antiarrhythmic drug. The pharmaceutical composition of claim 8, further comprising an antiarrhythmic drug. The pharmaceutical composition of claim 1, further comprising a nutritional supplement. The pharmaceutical composition of claim 10, further comprising a food supplement. The pharmaceutical composition of claim 11, wherein the nutritional supplement is selected from the group of magnesium, fish oil1. Фармацевтическая композиция, включающая физиологически приемлемое органическое и/или неорганическое соединение ванадия или комплекс для применения для поддержания нормогликемии у пациента в критическом состоянии, страдающего от острого стресса.2. Фармацевтическая композиция по п.1, где пациент в критическом сост
